CompanyGenscript Biotech Corp.
United States of America
GenScript is a leading biology CRO focusing exclusively on early drug discovery and development services. Built on it's assembly-line mode, one-stop solution, continuous improvement, and stringent IP protection, GenScript provides a comprehensive portfolio of services that include Bio-Reagent, Bio-Assay, Lead Optimization, and Antibody Drug Development which can be effectively integrated into your value chain and your operations. It strives with competence and confidence to meet your demand for ...
Private/Public:
public
Phone:1-732-317-5088
Fax:1-732-210-0262
Email:[email protected]
Website:http://www.genscript.com
Address:860 Centennial Ave.Piscataway, NJ 08854, United States of America
2002
Since
2
Countries
9
Top Service Categories
100
Sub-Service Categories
Top Services
API/Biologicals Production
API/Biologics development and manufacturing
Discovery and Preclinical
Specific Services-Discovery
Analytical
Analytical lab services
Bioanalytical
Bioanalytical assays
Diagnostics
Research Supplies
Life Sciences Supplies/Reagents
| Facility Type | Address | Telephone | City | Fax | Country | State Code | Service Categories | Facility Size | Year Built | Number Of Employees | Note |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Global Corporate Headquarters | 860 Centennial Ave.Piscataway, NJ 08854 | 1-732-317-5088 | Piscataway | 1-732-210-0262 | United States of America | NJ-New Jersey |
- (22.Feb.2021) SunRock Biopharma and GenScript ProBio Enter Into a Collaboration Agreement to Develop Novel Monoclonal Antibody Program
- (19.Feb.2021) Legend Biotech Announces Preliminary Results for the Year Ended December 31, 2020
- (18.Feb.2021) GenScript ProBio and Neoletix Announce Successful Completion of 200-Liter GMP Production Runs of Recombinant Coagulation FVIII Based on a Novel Production Technology
- (11.Feb.2021) GenScript Receives FDA Emergency Use Authorization for Use of cPass SARS-CoV-2 Neutralization Antibody Test in Convalescent Plasma Screening
- (13.Jan.2021) GenScript Submits Application With FDA for Use of cPass SARS-CoV-2 Neutralization Antibody Test in Convalescent Plasma Screening
- (07.Dec.2020) Through Strategic Collaboration With GenScript ProBio, Initium Therapeutics Plans to Utilize GenScript ProBio's Berkeley Lights Beacon Platform to Expand Their Antibody Drug Pipeline
- (06.Nov.2020) GenScript Receives FDA Emergency Use Authorization for World's First SARS-CoV-2 Neutralizing Antibody Detection Kit
- (06.Nov.2020) GenScript ProBio Chinese Brand Unveiled, CDMO Capacity Upgraded
- (19.Oct.2020) Beroni Group Announces Successful Completion of SARS-CoV-2 Pseudovirus Neutralization Assay for Treatment of COVID-19
- (17.Sep.2020) Expanding Their Existing Strategic Collaboration, GenScript ProBio Licensed Global Rights to Develop and Commercialize a SMAB Bispecific Antibody Molecule to REMD Biotherapeutics Inc
- (15.Sep.2020) Innatoss Laboratories Launches Neutralizing Antibody Public Testing Service for SARS-CoV-2 in Europe Using GenScript's cPass Kit
- (30.Aug.2020) GenScript Reports 2020 Interim Results and Provides Business Update
- (12.Aug.2020) Beroni Group Signs Agreement With Genscript Biotech Corporation to Conduct Further Study to Develop Nanobody-Based Medical Solution for COVID-19
- (10.Aug.2020) Cayman and GenScript Partner to Offer Neoantigen Profiling and Synthesis Expertise
- (04.Aug.2020) Beroni Group Has Successfully Constructed and Purified 24 Types of Nanobodies for Detection and Treatment of COVID-19
- (23.Jul.2020) GenScript Announces Publication of Clinical Data on New Method for Detecting COVID-19 Neutralizing Antibodies in Nature Biotechnology
- (21.Jul.2020) GenScript Launches CDMO Segment "GenScript ProBio" at Inaugural GenScript Cell and Gene Therapy Industry Development & Cooperation Forum
- (15.Jun.2020) Ethos Laboratories to Offer World's First Quantitative Surrogate Viral Neutralization Test to Evaluate COVID-19 Protective Immunity in the USA
- (03.Jun.2020) GenScript Files for Emergency Use Authorization of Rapid SARS-CoV-2 Neutralization Antibody Detection Kit
- (26.May.2020) GenScript Biotech Announces CE-IVD for Its Neutralizing Antibody Test Kit of SARS-CoV-2 and COVID-19 Diagnostic Products
- (14.May.2020) Duke-Nus, GenScript and A*STAR Launch First-In-The-World SARS-CoV-2 Serology Test to Detect Neutralising Antibodies Without Need of Containment Facility or Specimen
- (04.May.2020) Legend Biotech and Noile-Immune Biotech Announce Collaborative Research and Licensing Agreement
- (23.Apr.2020) Mount Sinai Researchers Collaborate with GenScript to Develop a COVID-19 Antibody to Treat Sick Patients
- (20.Apr.2020) DMed and GenScript Signed Strategic Agreement
- (07.Apr.2020) GenScript ProBio and Eutilex Enter Into Exclusive Strategic Collaboration on Plasmid and Virus Process Development and Manufacturing for CAR-T Programs
- (01.Apr.2020) SARS-CoV-2 Detection Kits Now Available for Research Labs
- (01.Apr.2020) GenScript Launches Neoantigen Specific Peptide Synthesis Service for Precision Immuno-Oncology Therapeutic Development
- (31.Mar.2020) GenScript Biotech Reports 2019 Financial Results and Provides Business Update
- (20.Mar.2020) GenScript Strives for Research Excellence Amidst the Global COVID-19 Pandemic